Related Experiment Video

Updated: Feb 4, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.8K

A novel prostate cancer immunotherapy using prostate-specific antigen peptides and Candida skin test reagent as an

Al-Ola Abdallah1,2, Hannah Coleman3, Mohamed Kamel4,5

  • 1Department of Internal Medicine, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

SAGE Open Medicine
|September 25, 2018
PubMed
Abstract

Insights

This study explores a novel prostate cancer immunotherapy using prostate-specific antigen peptides. Some patients showed immune responses, suggesting potential for this new cancer treatment.

Area of Science:

  • Immunology
  • Oncology
  • Vaccinology

Background:

  • A therapeutic vaccine for human papillomavirus utilized the Candida skin test reagent as an adjuvant for cell-mediated immunity.
  • This established technology is now being adapted for the development of prostate cancer immunotherapy.

Purpose of the Study:

  • To design and formulate a novel prostate cancer immunotherapy.
  • To evaluate the immunogenicity of prostate-specific antigen (PSA) peptides in prostate cancer patients.

Main Methods:

  • Selected PSA peptides were synthesized and assessed for solubility.
  • Langerhans cell maturation was analyzed using fluorescence-activated cell sorter analysis.
  • Peripheral immune cells from prostate cancer patients were tested for recognition of PSA peptides via interferon-gamma enzyme-linked immunospot assay.

Main Results:

  • Synthesized PSA peptides exhibited solubility in a specific buffer solution.
  • No maturation effects were observed on Langerhans cells from healthy donors.
  • Peripheral immune cells from 4 out of 10 prostate cancer patients demonstrated positive responses to one or more PSA peptides.

Conclusions:

  • A novel prostate cancer immunotherapy design and formulation are presented.
  • The observed immunogenicity of PSA peptides in a subset of prostate cancer patients warrants further investigation.
  • This research supports the continued development of this immunotherapy approach.
Keywords:
CandidaLangerhans cellsProstate-specific antigenpeptidesprostate cancer

More Related Videos

miRNA Expression Analyses in Prostate Cancer Clinical Tissues11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.2K
Isolation of Cancer Stem Cells From Human Prostate Cancer Samples07:16

Isolation of Cancer Stem Cells From Human Prostate Cancer Samples

Published on: March 14, 2014

14.6K

Related Concept Videos

Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
5.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.9K
Peptide Bonds02:43

Peptide Bonds

A peptide bond covalently attaches amino acids through a dehydration reaction. One amino acid's carboxyl group and another amino acid's amino group combine, releasing a water molecule. The resulting bond is the peptide bond. The products that such linkages form are peptides. As more amino acids join this growing chain, the resulting chain is a polypeptide. Each polypeptide has a free amino group at one end. This end has the N-terminal, or the amino-terminal, and the other end has a free...
83.1K
EDTA: Auxiliary Complexing Reagents01:26

EDTA: Auxiliary Complexing Reagents

EDTA titrations are usually carried out in highly basic conditions, where the fully deprotonated form of EDTA, Y4−, actively complexes with the free metal ions in the solution. Several metal ions precipitate as hydrous oxide (hydroxides, oxides, or oxyhydroxides) under these conditions, lowering the concentration of free metal ions in the solution. For this reason, auxiliary complexing agents or ligands such as ammonia, tartrate, citrate, or triethanolamine are used in EDTA titrations to...
1.4K
Acid Halides to Ketones: Gilman Reagent01:14

Acid Halides to Ketones: Gilman Reagent

Lithium dialkyl cuprate, also known as Gilman reagents, selectively reduces acid halides to ketones. The acid chloride is treated with Gilman reagent at −78 °C in the presence of ether solution to produce a ketone in good yield.
As shown below, the mechanism proceeds in two steps. First, one of the alkyl groups of the reagent acts as a nucleophile and attacks the acyl carbon of the acid chloride to form a tetrahedral intermediate. This is followed by the reformation of the carbon–oxygen...
4.1K
Preparation of Carboxylic Acids: Carboxylation of Grignard Reagents01:13

Preparation of Carboxylic Acids: Carboxylation of Grignard Reagents

Carboxylic acids can be prepared by the carboxylation of Grignard reagents (RMgX). This method is convenient for converting alkyl (primary, secondary or tertiary), vinyl, benzyl, and aryl halides to carboxylic acids with one additional carbon than the starting RMgX.
6.0K